Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?

Maria Cecília Mathias-Machado,Victor Hugo Fonseca de Jesus,Alexandre Jácome,Mauro Daniel Donadio,Marcelo Porfirio Sunagua Aruquipa,João Fogacci,Renato Guerino Cunha,Leonard Medeiros da Silva,Renata D'Alpino Peixoto

DOI: https://doi.org/10.3390/cancers16030679

2024-02-06

Cancers

Abstract:Gastric cancer (GC) remains a formidable global health challenge, ranking among the top-five causes of cancer-related deaths worldwide. The majority of patients face advanced stages at diagnosis, with a mere 6% five-year survival rate. First-line treatment for metastatic GC typically involves a fluoropyrimidine and platinum agent combination; yet, predictive molecular markers have proven elusive. This review navigates the evolving landscape of GC biomarkers, with a specific focus on Claudin 18.2 (CLDN18.2) as an emerging and promising target. Recent phase III trials have unveiled the efficacy of Zolbetuximab, a CLDN18.2-targeting antibody, in combination with oxaliplatin-based chemotherapy for CLDN18.2-positive metastatic GC. As this novel therapeutic avenue unfolds, understanding the nuanced decision making regarding the selection of anti-CLDN18.2 therapies over other targeted agents in metastatic GC becomes crucial. This manuscript reviews the evolving role of CLDN18.2 as a biomarker in GC and explores the current status of CLDN18.2-targeting agents in clinical development. The aim is to provide concise insights into the potential of CLDN18.2 as a therapeutic target and guide future clinical decisions in the management of metastatic GC.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the diagnosis and treatment challenges of gastric cancer (Gastric Cancer, GC). Specifically, the paper focuses on the potential application of Claudin 18.2 (CLDN18.2) as a new biomarker in gastric cancer. The following are the main research directions of the paper:

1. **Global Health Challenges of Gastric Cancer**:
- Gastric cancer is one of the leading causes of cancer - related deaths worldwide. Most patients are diagnosed at an advanced stage, and the 5 - year survival rate is only 6%.
- Current treatment regimens are mainly first - line chemotherapy, but there is a lack of effective predictive molecular markers to guide treatment selection.

2. **CLDN18.2 as a New Biomarker**:
- The paper focuses on exploring the potential of CLDN18.2 as a biomarker for gastric cancer.
- CLDN18.2 is a tight - junction protein. Normally, it is mainly expressed in gastric mucosal cells, but it is also often highly expressed in gastric cancer cells.
- The drug Zolbetuximab targeting CLDN18.2 has shown good results in combination with chemotherapy in recent clinical trials.

3. **Biological Functions of CLDN18.2**:
- CLDN18.2 plays an important role in maintaining cell polarity and barrier function.
- Changes in its expression level are related to the development, invasion, and metastasis of gastric cancer.
- Studies have found that high expression of CLDN18.2 is associated with certain types of gastric cancer (such as diffuse - type gastric cancer), but its relationship with survival rate is still unclear.

4. **Detection Methods of CLDN18.2**:
- Currently, CLDN18.2 is mainly detected by immunohistochemistry (IHC).
- Different studies have used different positive - definition criteria, but the FDA - approved VENTANA CLDN18 (43 - 14A) detection kit defines positive as the proportion of tumor cells with moderate - to - strong membrane staining intensity ≥ 75%.

5. **Prognostic and Predictive Value of CLDN18.2**:
- Multiple studies have shown that there is a certain association between the expression of CLDN18.2 and the staging and survival rate of gastric cancer, but these study results are not consistent.
- Although the role of CLDN18.2 as a prognostic marker is still unclear, its value in predicting the efficacy of Zolbetuximab has been preliminarily verified.

In conclusion, this paper aims to comprehensively review the latest progress of CLDN18.2 as a biomarker for gastric cancer and explore its potential application value in clinical treatment.